首页 | 本学科首页   官方微博 | 高级检索  
     

营养风险筛查工具(NRS-2002)对不可手术的食管鳞癌患者同步放化疗疗效和不良反应的相关性分析
引用本文:詹文明,陈芳洁,贾勇士,吴颖,戎惠,余黎,李渊. 营养风险筛查工具(NRS-2002)对不可手术的食管鳞癌患者同步放化疗疗效和不良反应的相关性分析[J]. 中华放射肿瘤学杂志, 2018, 27(8): 734-739. DOI: 10.3760/cma.j.issn.1004-4221.2018.08.005
作者姓名:詹文明  陈芳洁  贾勇士  吴颖  戎惠  余黎  李渊
作者单位:310014 杭州,浙江省人民医院 杭州医学院附属人民医院放疗科(詹文明、贾勇士),护理部(陈芳洁、吴颖、戎惠、余黎、李渊)
摘    要: 目的 研究营养风险筛查工具(NRS-2002)对不可切除的局部晚期食管鳞癌(LAESCC)患者接受同步放化疗治疗的疗效及生存结果影响。 方法 回顾性分析2013-2015年浙江省人民医院放疗科行根治性同步放化疗治疗的LAESCC患者 105例,营养状况的筛查使用营养风险筛查工具NRS-2002量表,率间比较采用χ2检验,Kaplan-Meier法计算生存率,Logrank法检验,Cox回归模型预后因素分析。 结果 37.1%的患者在同步放化疗前就存在营养风险,NRS-2002评分≥3分的患者≥3级不良反应发生率显著高于评分为 1~2分者(P=0.007),所有患者的中位生存(OS)和无进展生存(PFS)分别为17.0个月和11.8个月,NRS-2002评分≥3分组的患者OS和PFS均显著低于评分为 1~2分者(均 P=0.000),进一步行多因素分析发现,评分≥3分是OS (P=0.000)和PFS (P=0.001)降低的独立预后因素。 结论 NRS-2002工具表明食管癌患者存在较高营养风险,而治疗前评分≥3分提示与不良反应增加及生存降低显著相关,值得进一步研究和应用。

关 键 词:食管肿瘤/同步放化疗法  营养风险筛查工具  预后  
收稿时间:2017-09-04

Correlation analysis between the Nutritional Risk Screening Tool (NRS-2002),and clinical efficacy and adverse events of concurrent chemoradiotherapy for the esophageal squamous cell carcinoma patients
Zhan Wenming,Chen Fangjie,Jia Yongshi,Wu Ying,Rong Hui,Yu Li,Li Yuan. Correlation analysis between the Nutritional Risk Screening Tool (NRS-2002),and clinical efficacy and adverse events of concurrent chemoradiotherapy for the esophageal squamous cell carcinoma patients[J]. Chinese Journal of Radiation Oncology, 2018, 27(8): 734-739. DOI: 10.3760/cma.j.issn.1004-4221.2018.08.005
Authors:Zhan Wenming  Chen Fangjie  Jia Yongshi  Wu Ying  Rong Hui  Yu Li  Li Yuan
Affiliation:Department of Radiation Oncology (Zhan WM,Jia YS),Department of Nursing (Chen FJ,Wu Y,Rong H,Yu L,Li Y),Zhejiang Provincial People′s Hospital,People′s Hospital of Hangzhou Medical College,Hangzhou 310014,China
Abstract: Objective To investigate the effect of nutritional risk screening tool (NRS-2002) upon the clinical efficacy and survival outcomes in patients with unresectable locally advanced esophageal squamous cell carcinoma (LAESCC) receiving concurrent chemoradiotherapy. Methods Clinical data of 105 LAESCC patients treated with concurrent chemoradiotherapy in Zhejiang Provincial People′s Hospital from January 2013 to December 2015 were retrospectively analyzed. Nutritional status screening was performed using the NRS-2002 scale. The rate comparison was analyzed by using chi-square test. Kaplan-Meier survival analysis was adopted to calculate the survival rate. Log-rank test was utilized to statistically analyze the differences in survival outcomes. Cox regression model was used for uni-and multi-variate analyses. Results Prior to concurrent chemoradiotherapy,37.1% of patients had the nutritional risk. Patients with NRS-2002 score ≥3 had a significantly higher incidence of ≥ grade 3 toxic reactions compared with their counterparts obtaining NRS-2002 score of 1-2(P=0.007).The median overall survival (OS) and progression-free survival (PFS) of all patients were 17.0 and 11.8 months. The OS and PFS of patients with NRS-2002 score ≥ 3 were significantly lower than those of their counterparts obtaining NRS-2002 score of 1-2(both P=0.000).Multivariate analysis demonstrated that NRS-2002 score of ≥3 was an independent prognostic factor for OS (P=0.000) and PFS (P=0.001). Conclusions NRS-2002 tool reveals that patients with esophageal cancer possess a relatively high nutritional risk. Prior to treatment,NRS-2002 score of ≥3 is significantly correlated with an increasing risk of toxic reactions and decreasing survival rate,which is worthy of subsequent investigation.
Keywords:Esophageal neoplasms/concurrent chemoradiotherapy   Nutritional risk screening tool   Prognosis  
点击此处可从《中华放射肿瘤学杂志》浏览原始摘要信息
点击此处可从《中华放射肿瘤学杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号